Ontology highlight
ABSTRACT:
SUBMITTER: Usmani SZ
PROVIDER: S-EPMC6754719 | biostudies-literature | 2019 Aug
REPOSITORIES: biostudies-literature
Blood 20190703 8
Daratumumab, a human monoclonal antibody targeting CD38, is approved as monotherapy and in combination regimens for patients with multiple myeloma (MM). Currently, daratumumab is administered IV. The phase 1b PAVO (MMY1004) study evaluated subcutaneously administered daratumumab in combination with the recombinant human hyaluronidase PH20 enzyme (rHuPH20) in patients with relapsed or refractory MM. Part 1 of the study, reported here, evaluated a mix-and-deliver (MD) formulation of daratumumab an ...[more]